Salusin-β not salusin-α promotes vascular inflammation in ApoE-deficient mice via the I-κBα/NF-κB pathway

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zhou, Cheng Hua ^a   Liu, Lian ^a   Liu, Lu ^a   Zhang, Ming Xing ^a   Guo, Hao ^a   Pan, Jin ^a   Yin, Xiao Xing ^a   Ma, Teng Fei ^a   Wu, Yu Qing ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; SALUSIN ALPHA; SALUSIN BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CCL2 PROTEIN, MOUSE; I KAPPA B; MESSENGER RNA; NF-KAPPAB INHIBITOR ALPHA; SIGNAL PEPTIDE; TOR2A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DYSLIPIDEMIA; INTRACELLULAR TRANSPORT; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; VASCULITIS; ANIMAL; AORTA; C57BL MOUSE; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHEMOKINE CCL2; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; I-KAPPA B PROTEINS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84897977949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091468     Document Type: Article

References (24)

1. Libby P (2002) Inflammation in atherosclerosis. Nature 420:868-874.
2. Little PJ, Ballinger ML, Osman N (2007) Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vasc Health Risk Manag 3:117-124. (Pubitemid 46860721)
3. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
4. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143. (Pubitemid 34212626)
5. Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, et al. (2003) Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med 9:1166-1172. (Pubitemid 37173701)
6. Watanabe T, Nishio K, Kanome T, Matsuyama TA, Koba S, et al. (2008) Impact of salusin-alpha and -beta on human macrophage foam cell formation and coronary atherosclerosis. Circulation 117: 638-648.
7. Watanabe T, Suguro T, Sato K, Koyama T, Nagashima M, et al. (2008) Serum salusin-alpha levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res 31: 463-468. (Pubitemid 351597499)
8. Ti Y, Wang F, Wang ZH, Wang XL, Zhang W, et al. (2012) Associations of serum salusin-alpha levels with atherosclerosis and left ventricular diastolic dysfunction in essential hypertension. J Hum Hypertens 26: 603-609.
9. Zhou CH, Liu LL, Wu YQ, Song Z, Xing SH (2012) Enhanced expression of salusin-β contributes to progression of atherosclerosis in LDL receptor deficient mice. Can J Physiol Pharmacol 90: 463-471.
10. Nagashima M, Watanabe T, Shiraishi Y, Morita R, Terasaki M, et al. (2010) Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis 212: 70-77.
11. Sato K, Fujimoto K, Koyama T, Shichiri M (2010) Release of salusin-beta from human monocytes/macrophages. Regul Pept. 162: 68-72.
12. Koya T, Miyazaki T, Watanabe T, Shichiri M, Atsumi T, et al. (2012) Salusin-β accelerates inflammatory responses in vascular endothelial cells via NF-κB signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. Am J Physiol Heart Circ Physiol 303: H96-105.
13. Gehrig SM, Ryall JG, Schertzer JD, Lynch GS (2008) Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp Physiol 93: 1190-1198.
14. Constans J, Conri C (2006) Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 368: 33-47. (Pubitemid 43792418)
15. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW (2007) Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 101: 234-247. (Pubitemid 47344073)
16. Egashira K (2003) Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoat-tractant protein-1. Hypertension 41: 834-841.
17. Linton MF, Fazio S (2003) Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord 27: S35-40. (Pubitemid 38019186)
18. Reape TJ, Groot PHE (1999) Chemokines and atherosclerosis. Atherosclerosis 147: 213-225. (Pubitemid 29512252)
19. Chen F, Castranova V, Shi X, Demers LM (1999) New insights into the role of nuclear factor-kappa B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45: 7-17. (Pubitemid 29036378)
20. Lee EG, Boone DL, Chai S, Libby SL, Chien M, et al. (2000) Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289: 2350-2354.
21. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, et al. (2001) Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107: 675-683. (Pubitemid 32225353)
22. Sato K, Koyama T, Tateno T, Hirata Y, Shichiri M (2006) Presence of immunoreactive salusin-alpha in human serum and urine. Peptides 27: 2561-2566. (Pubitemid 44584413)
23. Fujimoto K, Hayashi A, Kamata Y, Ogawa A, Watanabe T, et al. (2013) Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator. PLoS One 8: e76714.
24. Du SL, Wang WJ, Wan J, Wang YG, Wang ZK, et al. (2013) Serum salusin-α levels are inversely correlated with the presence and severity of coronary artery disease. Scand J Clin Lab Invest. 2013 Apr 24. [Epub ahead of print].